These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 36905498)

  • 1. Patient and Healthcare Professional Preferences for Characteristics of Long-Acting Injectable Antipsychotic Agents for the Treatment of Schizophrenia.
    Robinson DG; Suett M; Wilhelm A; Chaijale N; Franzenburg KR; Gandhi S; Cloud B; Mychaskiw M
    Adv Ther; 2023 May; 40(5):2249-2264. PubMed ID: 36905498
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Long-Term Safety and Tolerability Study of TV-46000 for Subcutaneous Use in Patients with Schizophrenia: A Phase 3, Randomized, Double-Blinded Clinical Trial.
    Kane JM; Eshet R; Harary E; Tohami O; Elgart A; Knebel H; Sharon N; Suett M; Franzenburg KR; Davis GL; Correll CU
    CNS Drugs; 2024 Aug; 38(8):625-636. PubMed ID: 38954317
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Attitudes towards the administration of long-acting antipsychotics: a survey of physicians and nurses.
    Geerts P; Martinez G; Schreiner A
    BMC Psychiatry; 2013 Feb; 13():58. PubMed ID: 23414331
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TV-46000, A Long-Acting Subcutaneous Antipsychotic Agent, Demonstrated Improved Patient-Centered Outcomes in Patients with Schizophrenia.
    Citrome L; Suett M; Franzenburg KR; Eshet R; Elgart A; Davis Rd GL; Harary E; Tohami O; Mychaskiw MA; Kane JM
    Neuropsychiatr Dis Treat; 2024; 20():1901-1917. PubMed ID: 39399879
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Controversies Surrounding the Use of Long-Acting Injectable Antipsychotic Medications for the Treatment of Patients with Schizophrenia.
    Kane JM; McEvoy JP; Correll CU; Llorca PM
    CNS Drugs; 2021 Nov; 35(11):1189-1205. PubMed ID: 34636025
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment Patterns, Healthcare Resource Utilization and Costs Among Schizophrenia Patients Treated with Long-Acting Injectable Versus Oral Antipsychotics.
    Shah A; Xie L; Kariburyo F; Zhang Q; Gore M
    Adv Ther; 2018 Nov; 35(11):1994-2014. PubMed ID: 30269292
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antipsychotic Adherence and Rehospitalization in Schizophrenia Patients Receiving Oral Versus Long-Acting Injectable Antipsychotics Following Hospital Discharge.
    Marcus SC; Zummo J; Pettit AR; Stoddard J; Doshi JA
    J Manag Care Spec Pharm; 2015 Sep; 21(9):754-68. PubMed ID: 26308223
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Randomized, Open-Label, Multiple-Dose, Parallel-Arm, Pivotal Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Aripiprazole 2-Month Long-Acting Injectable in Adults With Schizophrenia or Bipolar I Disorder.
    Harlin M; Yildirim M; Such P; Madera-McDonough J; Jan M; Jin N; Watkin S; Larsen F
    CNS Drugs; 2023 Apr; 37(4):337-350. PubMed ID: 36961650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Practical dosing guidance for the management of clinician-administered injections of long-acting cabotegravir and rilpivirine.
    Patel P; Teichner P; Elliot E; Boffito M; Murray M; Polli JW; Baker M; Ford SL; Han K; Russu A; Crauwels H; D'Amico RD; Spreen WR; van Wyk J
    Ther Adv Infect Dis; 2023; 10():20499361231214626. PubMed ID: 38107552
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment Patterns, Health Care Resource Utilization, and Spending in Medicaid Beneficiaries Initiating Second-generation Long-acting Injectable Agents Versus Oral Atypical Antipsychotics.
    Pilon D; Tandon N; Lafeuille MH; Kamstra R; Emond B; Lefebvre P; Joshi K
    Clin Ther; 2017 Oct; 39(10):1972-1985.e2. PubMed ID: 28919292
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].
    Llorca PM; Miadi-Fargier H; Lançon C; Jasso Mosqueda G; Casadebaig F; Philippe A; Guillon P; Mehnert A; Omnès LF; Chicoye A; Durand-Zaleski I
    Encephale; 2005; 31(2):235-46. PubMed ID: 15959450
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Letter to the Editor: Rethinking The Cost Of Antipsychotic Treatment: The Average Cost Of The Drugs Used In Turkey In 2020.
    Yıldız M; Osman E
    Turk Psikiyatri Derg; 2022; 33(2):146-148. PubMed ID: 35730516
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A qualitative study of experiences with and perceptions regarding long-acting injectable antipsychotics: Part I-patient perspectives.
    Iyer S; Banks N; Roy MA; Tibbo P; Williams R; Manchanda R; Chue P; Malla A
    Can J Psychiatry; 2013 May; 58(5 Suppl 1):14S-22S. PubMed ID: 23945063
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patient Preferences for Attributes of Androgen Deprivation Therapies in Prostate Cancer: A Discrete Choice Experiment with Latent Class Analysis.
    Hauber B; Hong A; Hunsche E; Maculaitis MC; Collins SP
    Adv Ther; 2024 Oct; 41(10):3934-3950. PubMed ID: 39167332
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Baseline results from the European non-interventional Antipsychotic Long acTing injection in schizOphrenia (ALTO) study.
    Llorca PM; Bobes J; Fleischhacker WW; Heres S; Moore N; Bent-Ennakhil N; Sapin C; Loze JY; Nylander AG; Patel MX
    Eur Psychiatry; 2018 Aug; 52():85-94. PubMed ID: 29734130
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patient and prescriber perspectives on long-acting injectable (LAI) antipsychotics and analysis of in-office discussion regarding LAI treatment for schizophrenia.
    Potkin S; Bera R; Zubek D; Lau G
    BMC Psychiatry; 2013 Oct; 13():261. PubMed ID: 24131801
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patients' Preference for Long-Acting Injectable versus Oral Antipsychotics in Schizophrenia: Results from the Patient-Reported Medication Preference Questionnaire.
    Blackwood C; Sanga P; Nuamah I; Keenan A; Singh A; Mathews M; Gopal S
    Patient Prefer Adherence; 2020; 14():1093-1102. PubMed ID: 32753849
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence of concomitant oral antipsychotic drug use among patients treated with long-acting, intramuscular, antipsychotic medications.
    Aggarwal NK; Sernyak MJ; Rosenheck RA
    J Clin Psychopharmacol; 2012 Jun; 32(3):323-8. PubMed ID: 22544006
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics, Safety, and Tolerability of a 2-Month Dose Interval Regimen of the Long-Acting Injectable Antipsychotic Aripiprazole Lauroxil: Results From a 44-Week Phase I Study.
    Weiden PJ; Du Y; von Moltke L; Wehr A; Hard M; Marandi M; Walling DP
    CNS Drugs; 2020 Sep; 34(9):961-972. PubMed ID: 32621071
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single- and multiple-dose pharmacokinetic, safety, and tolerability profiles of olanzapine long-acting injection: an open-label, multicenter, nonrandomized study in patients with schizophrenia.
    Mitchell M; Kothare P; Bergstrom R; Zhao F; Jen KY; Walker D; Johnson J; McDonnell D
    Clin Ther; 2013 Dec; 35(12):1890-908. PubMed ID: 24184052
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.